Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.

News Market Reaction – CRIS

+4.35%

1 alert

+4.35% News Effect

On the day this news was published, CRIS gained 4.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2024-financial-results-and-hold-conference-call-on-may-7-2024-302131015.html

SOURCE Curis, Inc.

FAQ

When will Curis release its first quarter 2024 financial results?

Curis will release its first quarter 2024 financial results on May 7, 2024.

What is the focus of Curis, Inc.?

Curis is focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.

How can investors access the conference call hosted by Curis?

Investors can dial (800)-836-8184 from the United States or (646)-357-8785 from other locations to access the conference call. The call can also be accessed on the Curis website in the 'Investors' section.